Novo Nordisk Investigational Site
Groningen, 9728 NZ, Netherlands
NCT Number: NCT01517568
This trial is conducted in Europe. The aim of this trial is characterise the metabolic profile of liraglutide in plasma, urine, and faeces after a single injection of [3H]-liraglutide.
Looking for future studies?
Notify Me30 year–65 year
Male
Interventional
Phase 1
Groningen, 9728 NZ, Netherlands
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
A single dose of 0.75 mg will be given as a subcutaneous injection
Other names: [3H]-liraglutide
Novo Nordisk A/S
Industry
A Single-Centre, Open Label Trial Investigating the Metabolites in Plasma, Urine and Faeces After a Single Subcutaneous Dose of [3H]-Liraglutide to Healthy Subjects
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05970601
Diabetes, Diabetes Mellitus
Düsseldorf, Germany
View Trial DetailsNCT01508897
Diabetes, Diabetes Mellitus
Neu-Ulm, Germany
View Trial DetailsNCT01507285
Diabetes, Diabetes Mellitus
Manchester, United Kingdom
View Trial DetailsNCT03983733
Behavior, Behavior, Animal
Boston, Massachusetts, United States
View Trial Details